BioCryst Pharmaceuticals, Inc.BCRXNASDAQ
Loading
Year-over-year SG&A expense growth
| Period | Value |
|---|---|
| Q4 2025 | 15.38% |
| Q3 2025 | -5.00% |
| Q2 2025 | 5.96% |
| Q1 2025 | 2.48% |
| Q4 2024 | 23.64% |
| Q3 2024 | 6.26% |
| Q2 2024 | 2.96% |
| Q1 2024 | -7.60% |
| Q4 2023 | 27.12% |
| Q3 2023 | -0.68% |
| Q2 2023 | 6.54% |
| Q1 2023 | -4.56% |
| Q4 2022 | 35.85% |
| Q3 2022 | -2.89% |
| Q2 2022 | 10.89% |
| Q1 2022 | -3.12% |
| Q4 2021 | 1.13% |
| Q3 2021 | 32.92% |
| Q2 2021 | 19.04% |
| Q1 2021 | 5.38% |
| Q4 2020 | 22.05% |
| Q3 2020 | 23.86% |
| Q2 2020 | -12.49% |
| Q1 2020 | 51.25% |
| Q4 2019 | -10.62% |
| Q3 2019 | 35.52% |
| Q2 2019 | 38.81% |
| Q1 2019 | 38.93% |
| Q4 2018 | -43.33% |
| Q3 2018 | -16.53% |
| Q2 2018 | 24.75% |
| Q1 2018 | 61.96% |
| Q4 2017 | 40.53% |
| Q3 2017 | 17.96% |
| Q2 2017 | -7.33% |
| Q1 2017 | 19.41% |
| Q4 2016 | -7.08% |
| Q3 2016 | 1.17% |
| Q2 2016 | -15.19% |
| Q1 2016 | 18.04% |